Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells. - Yankelevich M; Thakur A; Modak S; Chu R; Taub J; Martin A; Schalk DL; Schienshang A; Whitaker S; Rea K; Lee DW; Liu Q; et al. (Research square, 2023)